Literature DB >> 15330178

Can recurrence of meningiomas be predicted?

Jean-Pierre Kalala1, Dominique Benoit, Leo De Ridder.   

Abstract

After resection of meningiomas the clinical evolution remains problematic, as no clear-cut predictive criteria are available. In vitro evaluation of meningiomas might help to predict their evolution in vivo after resection. For this goal a confrontation model was tested. A group of 105 patients operated for meningiomas between 1986 and 1997 were reviewed at 3, 5, 10 and 15 years for tumour evolution by tomodensitometry or magnetic resonance. At operation a fragment of these resected tumours was explanted for cell culture and was confronted with embryonic chick heart as a host tissue. The confrontation between tumour- derived cells and host tissue resulted in three different patterns: respectively a regressive, a non-invasive and an invasive pattern. Resection type, proliferation markers (Ki67 and PCNA) and in vitro confrontation patterns were significant (p<0.05) factors in predicting the postsurgical evolution of meningiomas. No correlation was found between proliferation markers and the behaviour in vitro, but invasion in vitro was strictly correlated with recurrence and malignancy of meningiomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15330178

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Progression of astrocytomas and meningiomas: an evaluation in vitro.

Authors:  L Maes; J P O Kalala; M Cornelissen; L de Ridder
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

2.  Malignant transformation of WHO grade I meningiomas after surgery or radiosurgery: systematic review and meta-analysis of observational studies.

Authors:  Satoshi Nakasu; Akifumi Notsu; Kiyong Na; Yoko Nakasu
Journal:  Neurooncol Adv       Date:  2020-10-16

3.  Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.

Authors:  Carl Wibom; Lina Mörén; Mads Aarhus; Per Morten Knappskog; Morten Lund-Johansen; Henrik Antti; A Tommy Bergenheim
Journal:  J Neurooncol       Date:  2009-04-07       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.